Jefferies LLC is the sales agent under an Open Market Sale Agreement for the $100,000,000 at-the-market portion. The May 7, 2025 filing gives a last reported sale price of $4.36 on May 5, 2025 and does not state a cash balance.
Latest Design Therapeutics news
We have not published a story on Design Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $12.9 million, plus short-term investments of $194.5 million, $207.4 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Design Therapeutics
Has Design Therapeutics raised money recently?
Our latest story on this, dated May 7, 2025: "Design Therapeutics files $300,000,000 shelf with $100,000,000 ATM sales agreement". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Design Therapeutics?
Design Therapeutics, Inc. trades under the ticker DSGN on NASDAQ.
Where is Design Therapeutics listed?
Design Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Design Therapeutics?
The SEC Central Index Key (CIK) for Design Therapeutics, Inc. is 1807120. Its filings are on SEC EDGAR.
How many shares does Design Therapeutics have outstanding?
62,581,651 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-03.
Which country or territory is Design Therapeutics listed under?
Our directory records Design Therapeutics, Inc. under United States.
What does Design Therapeutics do?
Our directory classifies Design Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Design Therapeutics?
The ISIN recorded for Design Therapeutics, Inc. is US25056L1035.
Does aibio.space cover Design Therapeutics?
aibio.space lists Design Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Design Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was Design Therapeutics's revenue last year?
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Design Therapeutics profitable?
Design Therapeutics, Inc. reported a net loss of $69.8 million for the fiscal year ended Dec 31, 2025, and used $54.4 million of cash in operations, per its annual report to the SEC.
How much does Design Therapeutics spend on research and development?
$59.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Design Therapeutics have?
$207.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Design Therapeutics (DSGN) stock news?
Our latest story on Design Therapeutics, dated May 7, 2025: "Design Therapeutics files $300,000,000 shelf with $100,000,000 ATM sales agreement". Jefferies LLC is the sales agent under an Open Market Sale Agreement for the $100,000,000 at-the-market portion. The May 7, 2025 filing gives a last reported sale price of $4.36 on May 5, 2025 and does not state a cash balance. Source.
Investor discussion: Design Therapeutics
Members talk about Design Therapeutics (DSGN). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Design Therapeutics, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:DSGN on TradingView.
SEC filings and registration
SEC name
Design Therapeutics, Inc.
CIK
1807120
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
DSGN (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
6005 HIDDEN VALLEY ROAD, CARLSBAD, CA, 92011
Phone
858-293-4900
Shares outstanding
62,581,651 as of 2026-07-29 (10-Q filed 2026-08-03)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Design Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DSGN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio